Rivipansel subcutaneous

Drug Profile

Rivipansel subcutaneous

Alternative Names: PF-06460031/PF-06744547; PF-06460031/rHuPH20; Rivipansel/PF-06744547; Rivipansel/rHuPH20

Latest Information Update: 10 Nov 2016

Price : $50

At a glance

  • Originator GlycoMimetics
  • Developer Pfizer
  • Class Anti-inflammatories; Antianaemics; Antineoplastics; Glycolipids; Naphthalenesulfonates; Pyrimidines; Small molecules
  • Mechanism of Action E-selectin inhibitors; L-selectin inhibitors; P selectin inhibitors; PCSK9 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Sickle cell anaemia

Most Recent Events

  • 07 Nov 2016 Discontinued - Phase-I for Sickle cell anaemia (In volunteers) in Belgium (SC)
  • 01 Apr 2016 Pfizer completes a phase I trial in Healthy volunteers in Belgium (SC) (NCT02217917)
  • 01 Oct 2015 Phase-I clinical trials in Sickle cell anaemia (In volunteers) in Belgium (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top